1887

Abstract

Accurate diagnosis of infection is essential for disease management. A clinical and molecular analysis of isolated from symptomatic patients at Groote Schuur Hospital, South Africa, was conducted to establish the most suitable clinical test for the diagnosis and characterization of locally prevalent strains. was detected in stool samples using enzyme-based immunoassays (EIA) and nucleic acid amplification methods, and their performance was compared with that of isolation using direct selective culture combined with specific PCR to detect the gene, toxin A and B genes and binary toxin genes. Toxigenic isolates were characterized further by ribotyping. Selective culture isolated 32 strains from 145 patients (22 %). Of these, the most prevalent (50 %) were of ribotype 017 (toxin AB) while 15.6 % were ribotype 001 (toxin AB). No ribotype 027 strains or binary toxin genes ( and ) were detected. The test sensitivities and specificities, respectively, of four commercial clinical diagnostic methods were as follows: Immuno Toxins A & B (40 % and 99.1 %), VIDAS Toxin A & B (50 % and 99.1 %), GenoType CDiff (86.7 % and 88.3 %) and Xpert (90 % and 97.3 %). Ribotype 001 and 017 strains had a 100 % detection rate by Xpert , 100 % and 93.3 % by GenoType CDiff, 75 % and 53.3 % by Immuno and 75 % and 60 % by VIDAS, respectively. The overall poor performance of EIA suggests that a change to PCR-based testing would assist diagnosis and ensure reliable detection of locally prevalent 017 strains.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000231
2016-04-01
2020-01-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/4/320.html?itemId=/content/journal/jmm/10.1099/jmm.0.000231&mimeType=html&fmt=ahah

References

  1. al-Barrak A., Embil J., Dyck B., Olekson K., Nicoll D., Alfa M., Kabani A.. 1999; An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital. Can Commun Dis Rep25:65–69[PubMed]
    [Google Scholar]
  2. Baker I., Leeming J. P., Reynolds R., Ibrahim I., Darley E.. 2013; Clinical relevance of a positive molecular test in the diagnosis of Clostridium difficile infection. J Hosp Infect84:311–315 [CrossRef][PubMed]
    [Google Scholar]
  3. Birgand G., Blanckaert K., Carbonne A., Coignard B., Barbut F., Eckert C., Grandbastien B., Kadi Z., Astagneau P.. 2010; Investigation of a large outbreak of Clostridium difficile PCR-ribotype 027 infections in northern France, 2006-2007 and associated clusters in 2008-2009. Euro Surveill15:195–197[PubMed]
    [Google Scholar]
  4. Boone J. H., Archbald-Pannone L. R., Wickham K. N., Carman R. J., Guerrant R. L., Franck C. T., Lyerly D. M.. 2014; Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality. Eur J Clin Microbiol Infect Dis33:1045–1051 [CrossRef][PubMed]
    [Google Scholar]
  5. Boseiwaqa L. V., Foster N. F., Thean S. K., Squire M. M., Riley T. V., Carson K. C.. 2013; Comparison of ChromID C. difficile agar and cycloserine-cefoxitin-fructose agar for the recovery of Clostridium difficile. Pathology45:495–500 [CrossRef][PubMed]
    [Google Scholar]
  6. Chia J.-H., Lai H.-C., Su L.-H., Kuo A.-J., Wu T.-L.. 2013; Molecular epidemiology of Clostridium difficile at a medical center in Taiwan: persistence of genetically clustering of A− B+ isolates and increase of A+B+ isolates. PLoS One8:e75471 [CrossRef][PubMed]
    [Google Scholar]
  7. Cohen S. H., Gerding D. N., Johnson S., Kelly C. P., Loo V. G., McDonald L. C., Pepin J., Wilcox M. H.. 2010; Society for Healthcare Epidemiology of America & Infectious Diseases Society of America Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol31:431–455 [CrossRef][PubMed]
    [Google Scholar]
  8. Crobach M.J.T., Dekkers O. M., Wilcox M. H., Kuijper E. J.. 2009; European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect15:1053–1066 [CrossRef][PubMed]
    [Google Scholar]
  9. Davies K. A., Longshaw C. M., Davis G. L., Bouza E., Barbut F., Barna Z., Delmée M., Fitzpatrick F., Ivanova K., other authors. 2014; Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis14:1208–1219 [CrossRef][PubMed]
    [Google Scholar]
  10. Drudy D., Harnedy N., Fanning S., Hannan M., Kyne L.. 2007; Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol28:932–940 [CrossRef][PubMed]
    [Google Scholar]
  11. Freeman J., Wilcox M. H.. 2003; The effects of storage conditions on viability of Clostridium difficile vegetative cells and spores and toxin activity in human faeces. J Clin Pathol56:126–128 [CrossRef][PubMed]
    [Google Scholar]
  12. Han S. B., Chang J., Shin S. H., Park K. G., Lee G. D., Park Y. G., Park Y.-J.. 2014; Performance of chromID Clostridium difficile agar compared with BBL C. difficile selective agar for detection of C. difficile in stool specimens. Ann Lab Med34:376–379 [CrossRef][PubMed]
    [Google Scholar]
  13. Hawkey P. M., Marriott C., Liu W. E., Jian Z. J., Gao Q., Ling T.K.W., Chow V., So E., Chan R., other authors. 2013; Molecular epidemiology of Clostridium difficile infection in a major chinese hospital: an underrecognized problem in Asia?. J Clin Microbiol51:3308–3313 [CrossRef][PubMed]
    [Google Scholar]
  14. Healthcare Commission 2006; Investigation into outbreaks of Clostridium difficile at Stoke Mandeville hospital, Buckinghamshire hospitals NHS trust London: Commission for Healthcare Audit and Inspection;
    [Google Scholar]
  15. Huang H., Fang H., Weintraub A., Nord C. E.. 2009; Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infect15:1170–1173 [CrossRef][PubMed]
    [Google Scholar]
  16. Humphries R. M., Uslan D. Z., Rubin Z.. 2013; Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol51:869–873 [CrossRef][PubMed]
    [Google Scholar]
  17. Keessen E. C., Hopman N.E.M., van Leengoed L. A., van Asten A.J.M., Hermanus C., Kuijper E. J., Lipman L.J.A.. 2011; Evaluation of four different diagnostic tests to detect Clostridium difficile in piglets. J Clin Microbiol49:1816–1821 [CrossRef][PubMed]
    [Google Scholar]
  18. Kelly C. P., LaMont J. T.. 2008; Clostridium difficile—more difficult than ever. N Engl J Med359:1932–1940 [CrossRef][PubMed]
    [Google Scholar]
  19. Komatsu M., Kato H., Aihara M., Shimakawa K., Iwasaki M., Nagasaka Y., Fukuda S., Matsuo S., Arakawa Y., other authors. 2003; High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur J Clin Microbiol Infect Dis22:525–529 [CrossRef][PubMed]
    [Google Scholar]
  20. Kuijper E. J., de Weerdt J., Kato H., Kato N., van Dam A. P., van der Vorm E. R., Weel J., van Rheenen C., Dankert J.. 2001; Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain. Eur J Clin Microbiol Infect Dis20:528–534 [CrossRef][PubMed]
    [Google Scholar]
  21. Lekalakala M. R., Lewis E., Hoosen A. A.. 2010; Clostridium difficile infections in a tertiary hospital: value of surveillance. J Hosp Infect75:328–329 [CrossRef][PubMed]
    [Google Scholar]
  22. Lemee L., Dhalluin A., Testelin S., Mattrat M.-A., Maillard K., Lemeland J.-F., Pons J.-L.. 2004; Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol42:5710–5714 [CrossRef][PubMed]
    [Google Scholar]
  23. McDonald L. C., Killgore G. E., Thompson A., Owens R. C. Jr, Kazakova S. V., Sambol S. P., Johnson S., Gerding D. N.. 2005; An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med353:2433–2441 [CrossRef][PubMed]
    [Google Scholar]
  24. Monot M., Eckert C., Lemire A., Hamiot A., Dubois T., Tessier C., Dumoulard B., Hamel B., Petit A., other authors. 2015; Clostridium difficile: new insights into the evolution of the pathogenicity locus. Sci Rep5:15023 [CrossRef][PubMed]
    [Google Scholar]
  25. Morgan D. J., Leekha S., Croft L., Burnham C.-A.D., Johnson J. K., Pineles L., Harris A. D., Dubberke E. R.. 2015; The importance of colonization with Clostridium difficile on infection and transmission. Curr Infect Dis Rep17:43 [CrossRef][PubMed]
    [Google Scholar]
  26. Novak-Weekley S. M., Marlowe E. M., Miller J. M., Cumpio J., Nomura J. H., Vance P. H., Weissfeld A.. 2010; Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol48:889–893 [CrossRef][PubMed]
    [Google Scholar]
  27. O'Connor D., Hynes P., Cormican M., Collins E., Corbett-Feeney G., Cassidy M.. 2001; Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol39:2846–2849 [CrossRef][PubMed]
    [Google Scholar]
  28. O'Connor J. R., Johnson S., Gerding D. N.. 2009; Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology136:1913–1924 [CrossRef][PubMed]
    [Google Scholar]
  29. Pépin J., Valiquette L., Alary M.-E., Villemure P., Pelletier A., Forget K., Pépin K., Chouinard D.. 2004; Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ171:466–472 [CrossRef][PubMed]
    [Google Scholar]
  30. Pépin J., Saheb N., Coulombe M.-A., Alary M.-E., Corriveau M.-P., Authier S., Leblanc M., Rivard G., Bettez M., other authors. 2005; Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis41:1254–1260 [CrossRef][PubMed]
    [Google Scholar]
  31. Perry J. D., Asir K., Halimi D., Orenga S., Dale J., Payne M., Carlton R., Evans J., Gould F. K.. 2010; Evaluation of a chromogenic culture medium for isolation of Clostridium difficile within 24 hours. J Clin Microbiol48:3852–3858 [CrossRef][PubMed]
    [Google Scholar]
  32. Planche T., Aghaizu A., Holliman R., Riley P., Poloniecki J., Breathnach A., Krishna S.. 2008; Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis8:777–784 [CrossRef][PubMed]
    [Google Scholar]
  33. Planche T. D., Davies K. A., Coen P. G., Finney J. M., Monahan I. M., Morris K. A., O'Connor L., Oakley S. J., Pope C. F., other authors. 2013; Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis13:936–945 [CrossRef][PubMed]
    [Google Scholar]
  34. Polage C. R., Gyorke C. E., Kennedy M. A., Leslie J. L., Chin D. L., Wang S., Nguyen H. H., Huang B., Tang Y.-W., other authors. 2015; Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med175:1792–1801 [CrossRef][PubMed]
    [Google Scholar]
  35. Rajabally N. M., Pentecost M., Pretorius G., Whitelaw A., Mendelson M., Watermeyer G.. 2013; The Clostridium difficile problem: a South African tertiary institution's prospective perspective. S Afr Med J103:168–172 [CrossRef][PubMed]
    [Google Scholar]
  36. Samie A., Obi C. L., Franasiak J., Archbald-Pannone L., Bessong P. O., Alcantara-Warren C., Guerrant R. L.. 2008; PCR detection of Clostridium difficile triose phosphate isomerase (tpi), toxin A (tcdA), toxin B (tcdB), binary toxin (cdtA, cdtB), and tcdC genes in Vhembe District, South Africa. Am J Trop Med Hyg78:577–585[PubMed]
    [Google Scholar]
  37. Shin B.-M., Kuak E. Y., Yoo S. J., Shin W. C., Yoo H. M.. 2008; Emerging toxin A-B+ variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea. Diagn Microbiol Infect Dis60:333–337 [CrossRef][PubMed]
    [Google Scholar]
  38. Sloan L. M., Duresko B. J., Gustafson D. R., Rosenblatt J. E.. 2008; Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol46:1996–2001 [CrossRef][PubMed]
    [Google Scholar]
  39. Spigaglia P., Mastrantonio P.. 2002; Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol40:3470–3475 [CrossRef][PubMed]
    [Google Scholar]
  40. Spigaglia P., Barbanti F., Mastrantonio P., Ackermann G., Balmelli C., Barbut F., Bouza E., Brazier J., Delmee M., other authors. 2011; Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother66:2227–2234 [CrossRef][PubMed]
    [Google Scholar]
  41. Stahlmann J., Schönberg M., Herrmann M., von Müller L.. 2014; Detection of nosocomial Clostridium difficile infections with toxigenic strains despite negative toxin A and B testing on stool samples. Clin Microbiol Infect20:O590–O592 [CrossRef][PubMed]
    [Google Scholar]
  42. Stubbs S. L., Brazier J. S., O'Neill G. L., Duerden B. I.. 1999; PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol37:461–463[PubMed]
    [Google Scholar]
  43. Stubbs S., Rupnik M., Gibert M., Brazier J., Duerden B., Popoff M.. 2000; Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett186:307–312 [CrossRef][PubMed]
    [Google Scholar]
  44. Surawicz C. M., Brandt L. J., Binion D. G., Ananthakrishnan A. N., Curry S. R., Gilligan P. H., McFarland L. V., Mellow M., Zuckerbraun B. S.. 2013; Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol108:478–498, quiz 499 [CrossRef][PubMed]
    [Google Scholar]
  45. Tenover F. C., Novak-Weekley S., Woods C. W., Peterson L. R., Davis T., Schreckenberger P., Fang F. C., Dascal A., Gerding D. N., other authors. 2010; Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol48:3719–3724 [CrossRef][PubMed]
    [Google Scholar]
  46. Terhes G., Urbán E., Sóki J., Nacsa E., Nagy E.. 2009; Comparison of a rapid molecular method, the BD GeneOhm Cdiff assay, to the most frequently used laboratory tests for detection of toxin-producing Clostridium difficile in diarrheal feces. J Clin Microbiol47:3478–3481 [CrossRef][PubMed]
    [Google Scholar]
  47. Vohra P., Poxton I. R.. 2011; Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile. Microbiology157:1343–1353 [CrossRef][PubMed]
    [Google Scholar]
  48. Weese J. S., Staempfli H. R., Prescott J. F.. 2000; Survival of Clostridium difficile and its toxins in equine feces: implications for diagnostic test selection and interpretation. J Vet Diagn Invest12:332–336 [CrossRef][PubMed]
    [Google Scholar]
  49. Wilcox M. H.. 2012; Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. Clin Microbiol Infect18:Suppl 613–20 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000231
Loading
/content/journal/jmm/10.1099/jmm.0.000231
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error